https://www.selleckchem.com/products/apatinib.html
082, €27.840 and €8.692, respectively. We identified three cost-drivers in the top 5% high-cost patients 1) expensive medication, 2) intensive care and 3) costs made at the respiratory unit. Patients with and without fatigue showed to have comparable mean costs. High-cost patients were more likely to have multiple organs involved due to sarcoidosis. We identified expensive medication as the main cost-driver in the top 5% high-cost patients with sarcoidosis. The study findings can help to tailor interventions for improving the quality o
Curtir
Comentario
Compartilhar
